The Efficacy and Mechanism Evaluation (EME) programme grant: Ref: 09/800/01 A randomised double blind placebo-controlled parallel group multi-centre trial of cannabinoids to slow progression in multiple sclerosis (Cannabinoid Use in Progressive Inflammatory Disease CUPID trial), (Chief Investigator for multicentre RCT.) £238,336 (Jul 2011 – Feb 2012).